SOHO 2023 | The importance of correctly identifying MGUS and SMM in patients to prevent progression to myeloma
Claudio Cerchione
• 6 Sep 2023
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the importance of correctly identifying patients with smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) in order to select therapies for patients who require treatment and prevent progression to active disease. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
